<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02697760</url>
  </required_header>
  <id_info>
    <org_study_id>104069_F</org_study_id>
    <nct_id>NCT02697760</nct_id>
  </id_info>
  <brief_title>The CZT Dynamic Myocardial Perfusion Imaging</brief_title>
  <acronym>CZT</acronym>
  <official_title>The Quantification, Clinical Application of Dynamic Imaging Using Cadmium-zinc-telluride (CZT) Cameras to Assess Myocardial Perfusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Far Eastern Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Far Eastern Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To develop and validate the noninvasive measurement of MBF and MFR by using dynamic imaging
      with a CZT camera, and evaluate the diagnostic and prognostic implications in various heart
      disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Absolute myocardial blood flow (MBF) and myocardial flow reserve (MFR) provide incremental
      diagnostic and prognostic information over relative perfusion alone. Recent development of
      dedicated cardiac SPECT cameras with better sensitivity and temporal resolution make dynamic
      SPECT imaging more practical. The potential roles of myocardial perfusion in subjects with
      cardiovascular risks and heart failure warrant further investigations.

      The present project aims to develop and validate the noninvasive measurement of MBF and MFR
      by using dynamic imaging with a CZT camera, and evaluate the diagnostic and prognostic
      implications.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary artery disease (CAD) diagnosis</measure>
    <time_frame>12 months after the index MPI</time_frame>
    <description>CAD defined as more than 50% stenosis in any vessel by coronary angiography or computed tomography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE (major adverse cardiac events)</measure>
    <time_frame>5 years after the index MPI</time_frame>
    <description>revascularization, acute myocardial infarction, hospitalization for heart failure, cardiac death, non-cardiac death</description>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Cardiac Disease</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>thallium-201</intervention_name>
    <description>Thallium (Tl-201) myocardial single photon emission tomography, dynamic imaging</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with clinically suspected coronary artery disease, heart failure, or intermediate
        and high cardiovascular risks
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Coronary heart disease

          2. Clinical diagnosis of heart failure

          3. Clinical diagnosis of metabolic diseases (such as metabolic syndrome, obesity,
             diabetes, hyperlipidemia, micro vascular diseases, etc.), heart failure or coronary
             heart disease in high-risk groups persons.

        Exclusion Criteria:

        Significant systemic disease (except heart disease) such as cirrhosis, end-stage renal
        disease or active malignancy, estimated life expectancy of less than three months, persons;
        pregnant or lactating women have the possibility of pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yen-Wen Wu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Far Eastern Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yen-Wen Wu, MD, PhD</last_name>
    <phone>886-2-8966-7000</phone>
    <phone_ext>1090</phone_ext>
    <email>wuyw0502@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Far Eastern Memorial Hospital</name>
      <address>
        <city>New Taipei City</city>
        <zip>220</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yen-Wen Wu, MD, PhD</last_name>
      <phone>886-2-8966-7000</phone>
      <phone_ext>1090</phone_ext>
      <email>wuyw0502@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yen-Wen Wu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2016</study_first_submitted>
  <study_first_submitted_qc>February 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2016</study_first_posted>
  <last_update_submitted>February 17, 2018</last_update_submitted>
  <last_update_submitted_qc>February 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Far Eastern Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Yen-Wen Wu</investigator_full_name>
    <investigator_title>Chief of Cardiology Division of Cardiovascular Medical Center, Far Eastern Memorial Hospital</investigator_title>
  </responsible_party>
  <keyword>cadmium-zinc-telluride，CZT cameras</keyword>
  <keyword>myocardial blood flow，MBF</keyword>
  <keyword>myocardial flow reserve，MFR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

